# To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

Study · id `cardio:ct-nct01682564` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01682564](<https://clinicaltrials.gov/study/NCT01682564>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01682564

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.

## Technical summary

Registry record NCT01682564. Randomized; no masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 169 participants (enrolled count; ClinicalTrials.gov record NCT01682564, source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01682564, source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01682564, source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01682564, source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01682564, source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01682564-2015-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
- Acronym: CANTABILE
- Condition: Hypertension
- Condition: Congestive Heart Failure
- Intervention (Drug): Candemore tablet
- Intervention (Drug): Atacand tablet
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 481126357a70769cfbf784f1685e32ef20b1a0185cf379bf7d26e66e8228c735
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
